Sponsor: University of Oxford
Clinical Trials.gov Number: NCT02145416
Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)
A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.
Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.
Open to recruitment.
Target recruitment: 30 (27 evaluable) patients.
Current recruitment: 19 (September 2016).
- Histologically confirmed invasive primary squamous carcinoma of the anus.
- Patients must be fit and scheduled to receive radical CRT with curative intent.
- Any stage ≥ T2N0
- Male or female, Age ≥ 18 years
- The patient is willing and able to comply with the images and protocol for the duration of the study
- Written (signed and dated) informed consent
- Pregnant or breast-feeding women or women of childbearing potential unless effective methods of contraception are used
- Previous pelvic radiotherapy
- Patients with a pacemaker or any other implanted metal which would preclude MRI scan
- Patients receiving radiotherapy with palliative intent
- Active medical or psychological illness that would render the patient unsuitable for the additional imaging proposed in this study, at the discretion of the investigator
To evaluate changes on Diffusion Weighted MRI (DW MRI) during CRT in anal cancer.
To evaluate changes on functional imaging (Dynamic Contrast Enhanced MRI (DCE MRI), Perfusion Computed Tomography (pCT), Blood Oxygen-dependent Magnetic Resonance Imaging (BOLD MRI), Fludeoxyglucose Positron Emission Tomography (FDG PET)) during CRT in anal cancer.
To correlate findings on different functional images.
To correlate baseline functional images with outcome of CRT.
To correlate the change in functional images over CRT with outcome of CRT.
To evaluate the use of T1 mapping in anal cancer.
To evaluate use of dynamic data acquired during FDG PET scan.
To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.
Trial opened: 16 October 2014
Planned accrual completion: November 2017
Final analysis and publication: April 2019
Trial duration: 41 Months